Amphetamine-type stimulant use and self-harm: protocol for a systematic review of observational studies

Craig Cumming,1 Gregory Armstrong,2,3 Rohan Borschmann,2,4 James A Foulds,5 Giles Newton-Howes,6 Rebecca McKetin,7 Shannen Vallesi,1 David Preen,1 Jesse Young2,4

ABSTRACT

Introduction Amphetamine type stimulant (ATS) use and self-harm are both major public health concerns globally. Use of ATS is associated with a range of health and social problems, and has been increasing internationally in the last decade. Self-harm and ATS use share a number of underlying risk factors and occur at elevated rates in marginalised groups with high rates of exposure to trauma. The relationship between self-harm and ATS use is likely complex, and the causal pathway may run in either direction. A comprehensive review, synthesis and analysis of the evidence are warranted to investigate this relationship and inform policy and practice.

Methods and analysis We will search the Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, PsycINFO and Scopus databases for relevant observational studies published in peer-reviewed journals. The initial search was conducted on 5 February 2021, with a final search expected on 1 February 2022. All studies will be independently screened by two reviewers, first on title and abstract, and then on full-text to determine inclusion in the review. We place no restriction on the population that studies investigate, our exposure of interest is both prescription and illicit ATS use, comparators will be those not currently using ATS, and our primary outcome of interest is the prevalence of self-harm. Data will be extracted using a predesigned template, and pooled prevalence and pooled measures of effect for the association between ATS use and self-harm. If sufficient data are available, we will perform multiple meta-analyses to produce pooled measures of effect for each measure of ATS exposure, as well as different population sub-groups. The Methodological Standard for Epidemiological Research scale will be used to assess study quality, and Egger’s test and I² values will be used to assess publication bias and heterogeneity, respectively.

Ethics and dissemination No ethical approval is required for this review. We will only synthesise information from published studies that were conducted with ethical approval, so no individual participant data will be used. We will disseminate our findings via publication in a peer-reviewed journal, national and international conference presentations, and presentations to stakeholders in the community.

Trial registration number This study has been registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42021226562).

Strengths and limitations of this study

- These are both important public health issues globally, and no systematic reviews have previously been performed to synthesise the literature.
- A comprehensive search strategy of five key medical databases, designed with the input of a university librarian, will be used; this will be supplemented by a hand search of the citation and reference list of all included studies.
- If sufficient data are available, a comprehensive analysis plan will be used to ensure all clinically relevant covariates are examined.
- Studies not published in English will not be included.
- In the event a small number of eligible studies are found, heterogeneity between study populations and study design may prevent meta-analysis or the direct comparison between studies.

INTRODUCTION

The use of amphetamine type stimulants (ATS) is a major public health concern internationally. Estimates suggest that approximately 27 million people globally used ATS in 2018.4 Since 2016, countries such as the USA, UK, Germany, The Netherlands, Norway and New Zealand have seen increases in the prevalence of illicit amphetamine use.1 Additionally, wastewater analysis across 140 European cities suggests an upward trend since 2011 in the quantity of amphetamines being consumed.3 In Australia, there has been a reduction of methamphetamine use among people aged 14 and older since 2001.1 However, wastewater analysis suggests an increase of 37% in consumption of methamphetamine between 2016 and 20195; likely indicating increasingly heavy use among those who are using. Evidence from the Association of Southeast Asian Nations shows a 93% increase in treatment admissions for ATS-related treatment between 2017 and 2019, and an 81% increase in the number of people committing ATS-related offences during the same period.2 It is
Multiple health and social problems are associated with ATS use. These include poor mental health (including depression, psychosis and suicidal behaviour), hypertension and cardiovascular problems, violence perpetration, and contact with the criminal justice system. Accordingly, there is emerging evidence of increasing ATS-related hospitalisations and health service use in many parts of the world, placing excess strain on already overburdened services sectors.

Self-harm is defined as ‘intentional self-poisoning or self-injury, irrespective of type of motive or the extent of suicidal intent’ and is a major public health issue internationally. ATS use and self-harm share a number of underlying risk factors such as depression and anxiety, and life stressors and traumatic events such as physical, sexual and psychological abuse.

Both ATS use and self-harm also occur at higher rates in marginalised groups who have experienced high rates of trauma such as those who have contact with the justice system, people who experience homelessness, and lesbian, gay, bisexual, transgender, queer, intersex plus (LGBTQIA+) groups. It is likely that the relationship between ATS use and self-harm is complex; however, it is likely that depression, anxiety, trauma and stressful life events may act as mediators. Conversely, reverse causation (ie, self-medication with ATS for symptoms associated with self-harm) is also plausible.

To our knowledge, no prior systematic review has synthesised the literature and quantified the association between ATS use and self-harm. Accordingly, we will conduct a systematic review which aims to: (1) synthesise the peer-reviewed evidence on the prevalence of self-harm among people who use ATS and (2) summarise and quantify the association between ATS use and self-harm, by comparing self-harm in populations that do and do not use ATS. We will use our findings to inform policy and practice in alcohol and other drugs treatment settings aimed at preventing self-harm and identify key gaps in the knowledge base to direct future research in this area.

**METHODS AND ANALYSIS**

This protocol adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Protocols and has been registered with International Prospective Register of Systematic Reviews (PROSPERO) at the University of York, UK (CRD42021226562).

**Patient and public involvement**

This study was designed without patient or public involvement.

**Eligibility criteria**

Our eligibility and exclusion criteria for this review are presented in table 1.

**Participants**

We will place no restriction on the populations that studies identified by our search may include. Studies including individuals of any age, and those focussing on subpopulations who have used ATS such as same-sex attracted and gender diverse people, and those with mental illness, will be included.

**Exposure measures**

Our exposure of interest is use of prescription and/or illicit ATS; a list of included ATS is provided in box 1.

Studies that identify ATS exposure from any one of the following measures will be considered for inclusion: self-report, valid screening/diagnostic tools and/or International Classification of Diseases Tenth Revision codes (F15, X61, T43.6) where diagnoses are recorded in administrative data. All available data on ATS exposure in addition to those reporting ATS use disorder will be extracted and analysed for: (1) the prevalence of self-harm among people who use ATS and (2) association between ATS use and self-harm. Where available, we will extract data on patterns of ATS use which may include frequency or quantity of use, age of initiation and route of administration. Subject to having sufficient data available, we will compare self-harm between (1) people with and without ATS use disorder; and (2) people with ATS use disorder and other (non-ATS) substance use disorders.

**Outcome measures**

Our primary outcome of interest is the prevalence of self-harm; characterised as intentional self-injury or poisoning irrespective of suicidal intent. Studies investigating suicide (ie, fatal self-harm) or suicidal ideation only will not be included.
be excluded. Studies that ascertain self-harm by any of the following measures will be considered for inclusion: clinical assessment, administrative health records and/or self-report.

Study design
We will include observational studies that report individual-level quantitative data. Accordingly, we will exclude studies with the following designs: case reports and case studies (ie, studies reporting on one individual), case series, trials, observational studies not using individual-level analysis (eg, ecological studies) and prior reviews. We will include cohort, case-control and cross-sectional studies pursuant to the Cochrane handbook definition of observational studies.36

Search strategy
We will search the following five key health and medical databases for peer-reviewed literature from their inception until the most recent available literature on the date of performing our final search: Medline, Embase, CINAHL, PsycINFO and Scopus. Our initial search was performed on 5 February 2021, we anticipate performing a final update on 1 February 2022. The search strategy used for Medline (Ovid) is displayed in Box 2.

A librarian from the University of Western Australia was consulted during the development of the search strategy. Once full-text screening is completed, the citation and reference lists of all included studies will be searched for additional studies that meet our inclusion criteria but were not identified by our literature search. No restrictions will be placed on the publication year or location.

Study selection and screening
The research team will use reference management software EndNote37 to import studies identified from each database search. Duplicates will be removed in EndNote and all unique studies will be imported into systematic review software Covidence38 for screening. Two authors (CC and SV) will independently screen the title and abstract of all identified studies based on our inclusion and exclusion criteria. Conflicts on the eligibility of a study will be resolved via discussion between the two screening authors, and where consensus cannot be reached, a third author (JY) will be engaged to achieve consensus. Cohen’s kappa statistic39 will be used to estimate the inter-rater reliability.

Full-text articles will be screened by two authors, with any conflicts resolved by consensus with a third author. Reasons for exclusion will be recorded. Primary reasons for exclusion will include: (1) incorrect exposure, (2) incorrect outcome, (3) incorrect study design, (4) no usable data and (5) unable to obtain the full article. Where study eligibility is unclear from the published full-text, original study authors will be contacted for clarification. Where it is determined (based on title, authors, locations and dates) that multiple studies have used the same dataset and report the same measures (ie, prevalence and/or measure of association), the study with the longest follow-up time will be included, and the other studies will be excluded from the review.

Data extraction
A standardised Excel form will be developed a priori by the research team for the purposes of data extraction. Data extraction will be performed by one member of the research team using the standardised form. A second research team member will check the extracted data to identify and correct any errors, and a third research team member will resolve any conflicts by consensus that may arise. A list of fields to be extracted is provided in table 2.

Risk of bias assessment
The risk of bias assessment will be performed independently by two authors, with a third author resolving any conflicts that cannot be resolved by consensus. The Methodological Standard for Epidemiological Research (MASTER) scale40 will be used to assess the risk of bias. The MASTER scale provides a single unified tool to assess the risk of bias across different study design types. This is done

---

**Box 1** Substances included in exposure of interest

- Methamphetamine
- Amphetamine
- N-Methyl-3,4-methylenedioxyamphetamine
- Methylphenidate
- Methcathinone
- Fenetyline
- Ephedrine
- Pseudoephedrine
- Bupropion
- Dextroamphetamine
- Mixed amphetamine salts (eg, Adderall)
- Lisdexamfetamine
- Phentermine

**Box 2** Search strategy Medline (Ovid)

1. expExp Amphetamine amphetamine/
2. exp 3,4-methylenedioxyamphetamine/ or exp n-methyl-3,4-methylenedioxyamphetamine/
3. (((ATS or stimulant* or amphetamine* or amfetamine* or stimulant* or meth) adj2 amphetamine) or speed or ice or centramina or desoxynepheredrine or fenamine or mydrial or phe

---

by assessing each study for the presence of a number of methodological standards aimed at addressing the risk of bias across six potential bias domains (selection, information, design-related, analytic, confounding, external validity).39-40 Adopting the approach of previous systematic reviews,3 4 41 we will discuss the possible risk of bias and study quality in text and generate a score summarising each study’s quality by using the proportion of safeguards against bias that each study incorporated. This is done by using the top scoring study in the review as a reference and assigning each other study a score relative to the reference study’s score. For example, if the reference study has a score of 10, and another study has a score of 8, the other study will be assigned a bias safeguard score of 80%. The quality summary scores will be used for sensitivity analyses, but not to weight analyses, as recommended by the Meta-Analysis Of Observational Studies in Epidemiology study group.42

### Statistical analysis

Data analysis will be led by CC with assistance from coauthors. The characteristics of the included studies will be summarised and described. This summary will include study setting and country, study quality, and measures used in the assessment of ATS use and ascertainment of self-harm.

If there are sufficient studies included in the review, meta-analysis will be conducted to determine the pooled prevalence of self-harm among people who use ATS and a pooled measure of effect for the association between use of ATS and self-harm. If sufficient data are available, we will perform multiple meta-analyses to produce pooled measures of effect for each measure of ATS exposure used in the included studies (eg, any ATS use, frequency of ATS use, ATS use disorder) and self-harm. Where studies provide both adjusted and unadjusted effects measures, we will use the adjusted measure consistent with the Cochrane Handbook.36 I² values will be estimated and used to assess heterogeneity. If there are sufficient included studies, meta-regression will also be conducted to investigate the impact of age and study design on pooled estimates if there are sufficient data to do so. Potential publication bias will be assessed using Egger’s test.43 The meta-analyses results will be presented in forest plots provided there are at least two studies per analysis with acceptable heterogeneity.36 The forest plots will be complemented with a harvest plot if appropriate to do so.44 If there are insufficient data to conduct meta-analyses, results will be presented using a harvest plot in order to examine study quality, correlations between study characteristics and estimated effect measures.44-45 Informed by the guidance and principles outlined by the Economic and Social Research Council Methods Program,15 the harvest plot will be accompanied by a narrative synthesis of the findings of studies included in the review. All statistical analysis will performed using Stata V.16.46

Given the evidence of changes in the prevalence of self-harm between adolescence and adulthood,47 48 where there are sufficient data extracted we will conduct subgroup/sensitivity analyses stratifying by either a cut-off of <18/>=18 years of age or mean/median age if the data do not permit an age of majority cut-off.

Given the evidence of an association between amphetamine use and mental illness,49 50 if possible we plan to also stratify our analyses by individuals with and without a diagnosed mental illness. Subgroup analyses will also be used to compare studies in which individuals have and have not reported being diagnosed with a substance use disorder. If data from the included studies permit, analyses of subgroups of studies involving LGBTQIA+ populations, people who are homeless, and people with criminal justice system contact will also be conducted as ATS use prevalence is elevated in these groups.27-29 51 52

If there are a sufficient number of studies included in the review,53 separate analyses will be performed for groups of studies based on: type of ATS used; method of self-harm; length of study follow-up time (dichotomised by less or greater than 1 month); and sex of participants. Additionally, analyses will be performed on a subset of studies investigating ATS types that do not have strong hallucinogenic properties (ie, studies investigating methylenedioxymethamphetamine alone would be excluded from these analyses). This will be done to investigate whether any association that may be found between ATS use and self-harm is mediated by psychosis, given the association between psychosis and self-harm.54 Finally, if there are sufficient data, we will perform a subgroup analysis of studies that report data on ATS withdrawal and

### Table 2 Fields to be included in data-extraction form

<table>
<thead>
<tr>
<th>Author and year of study</th>
<th>Exposed/non-exposed conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geographic location of study</td>
<td>Median length of follow-up time and variance</td>
</tr>
<tr>
<td>Study setting</td>
<td>Loss to follow-up</td>
</tr>
<tr>
<td>Study design</td>
<td>Statistical methods used (ie, controlling for confounders, examining subgroups and interactions, accounting for missing data and loss to follow-up, sensitivity analyses)</td>
</tr>
<tr>
<td>Participant population/group</td>
<td>How bias was addressed</td>
</tr>
<tr>
<td>Method of recruitment</td>
<td>Measure of association used</td>
</tr>
<tr>
<td>Data source(s)</td>
<td>Participant descriptors (eg, total number, number in each condition, sex, mean/median age, other demographic characteristics of interest)</td>
</tr>
<tr>
<td>Outcome variables</td>
<td>Main results (unadjusted/adjusted estimates)</td>
</tr>
<tr>
<td>Exposure variables</td>
<td>Subgroup analyses results</td>
</tr>
<tr>
<td>Predictor variables</td>
<td>Any conflicts declared</td>
</tr>
<tr>
<td>Potential confounders</td>
<td>Any funding declared</td>
</tr>
</tbody>
</table>
self-harm to assess a possible relationship between these two issues.

Sensitivity analyses will be conducted which exclude studies assessed to be low quality based on the quality assessment scores (using a median split) to understand the potential impact study quality and risk of bias may have on outcomes; conceptually consistent with the MASTER scale.40

Finally, we will assess the strength of the body of evidence of all included studies using the grading of recommendations, assessment, development and evaluation methodology.39

Data statement
The data extracted from studies included in this review will be published in the University of Western Australia research repository, accessible via doi: 10.26182/2a6h-y731.

ETHICS AND DISSEMINATION
Ethics
This systematic review will synthesise data from existing publications, no participants will be recruited and no new participant information will be collected. No ethics approval was required for this review.

Dissemination
We believe that this will be the first review to systematically search and synthesis evidence investigating the relationship between ATS use and self-harm. It is likely that a substantial proportion of the increase in health service use related to ATS will be attributable to self-harm. Understanding the magnitude of this effect will assist policy-makers to estimate the impact of population-level interventions for stimulant use on health service utilisation related to self-harm. Our findings will likely be of interest to academic researchers, clinicians, health service providers and key agency stakeholders and policymakers, as well as people who use or have used ATS. We will disseminate our findings via peer-reviewed publication in an academic journal, and will present our results at conferences. We will also provide our results to relevant professional organisations and government agencies so that it can be disseminated and translated to their members and staff respectively. As part of the publication process, we will publish a plain language synopsis of our work which will include links to the peer-reviewed publication.

Author affiliations
1School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia
2The University of Melbourne, Melbourne, Victoria, Australia
3Nossal Institute for Global Health, Melbourne School of Population and Global Health, Carlton, Victoria, Australia
4Justice Health Unit, Centre for Health Equity, Melbourne School of Population and Global Health, Carlton, Victoria, Australia
5Department of Psychological Medicine, University of Otago Christchurch, Christchurch, Canterbury, New Zealand
6Department of Psychological Medicine, University of Otago, Dunedin, New Zealand
7National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia
8Department of Clinical Psychology, University of Otago, Dunedin, New Zealand
9School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia
10Centre for Addiction and Mental Health, Vancouver, British Columbia, Canada

REFERENCES
34. Veritas Health Innovation. Cochrane systematic review software program. Melbourne, Australia.